Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 4/20 | 0.47 |
| ▸ | CNR2 | P34972 | 3/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3370193 | 0.85 | FAAH (0.50) | CNR1CNR2FAAHPPARGPPARA | |
| SCHEMBL3374627 | 0.83 | CNR1 (0.53) | OPRL1CNR1CNR2PPARGPPARA | |
| SCHEMBL1395400 | 0.75 | FAAH (0.45) | FAAHOPRM1MEN1KMT2AAOC3 | |
| SCHEMBL1395396 | 0.75 | FAAH (0.45) | FAAHOPRM1MEN1KMT2AAOC3 | |
| SCHEMBL27516632 | 0.72 | HDAC4 (0.46) | CNR2PPARGPPARAMEN1KMT2A | |
| SCHEMBL6143613 | 0.71 | FAAH (0.44) | FAAHPPARG | |
| SCHEMBL3371814 | 0.70 | CNR1 (0.56) | OPRL1CNR1CNR2 | |
| SCHEMBL13068718 | 0.67 | CNR1 (0.54) | OPRL1CNR1CNR2 | |
| SCHEMBL27608061 | 0.67 | MDM2 (0.48) | OPRL1CNR1CNR2PKMRAB9A | |
| SCHEMBL6246016 | 0.67 | CTSS (0.47) | PPARGPPARAMEN1KMT2ANOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7667053-B2 | Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders | MERCK & CO., INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7390835-B2 | Aralkyl amines as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-20070088058-A1 | 3-(1(S)(4-chlorobenzyl)-2(S)-((2-hydroxy-2-methyl-1-phenylpropyl)amino)propyl)-benzonitrile; obesity; potentiation; antagonists | MERCK SHARP & DOHME CORP. | 2007-04-19 | — | — | US | disclosed |
| US-20050203112-A1 | Bicyclic amides | MERCK SHARP & DOHME CORP. | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203112-A1 | Bicyclic amides | CNR1, CNR2, FAAH | OPRL1 10/4885CNR1 1/4885CNR2 2/4885 |
| US-20070088058-A1 | 3-(1(S)(4-chlorobenzyl)-2(S)-((2-hydroxy-2-methyl-1-phenylpropyl)amino)propyl)-benzonitrile; obesity; potentiation; antagonists | CNR2, CNR1, CHRNA4 | OPRL1 22/4885CNR1 2/4885CNR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.